The Blepharospasm drugs in development market research report provides comprehensive information on the therapeutics under development for Blepharospasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Blepharospasm. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Blepharospasm - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Blepharospasm and features dormant and discontinued products.

GlobalData tracks five drugs in development for Blepharospasm by four companies/universities/institutes. The top development phase for Blepharospasm is phase ii with two drugs in that stage. The Blepharospasm pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Blepharospasm pipeline products market are: Addex Therapeutics, Daewoong Pharmaceutical and AbbVie.

The key targets in the Blepharospasm pipeline products market include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25), and Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5).

The key mechanisms of action in the Blepharospasm pipeline product include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor with three drugs in Phase III. The Blepharospasm pipeline products include four routes of administration with the top ROA being Intradermal and two key molecule types in the Blepharospasm pipeline products market including Protein, and Small Molecule.

Blepharospasm overview

Blepharospasm is involuntary eyelid movements like blinking or twitching. It is caused due to abnormalities in an area of the brain that impacts muscle movement. Symptoms include uncontrollable blink, squint, wink, twitch, or squeezing closed one or both eyes. Diagnosis relies on physical examination, medical history, and ruling out other possible causes. Treatment for blepharospasm can include stress management, botulinum type A toxin injections, medications such as lithium and diazepam, and surgery.

For a complete picture of Blepharospasm’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.